Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2072 in Primary Aldosteronism
NCT07917039Phase 2Not yet recruiting
- Sponsor
- InnovStone Therapeutics
- Start
- Nov 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
A Phase 2 trial of SYH2072 in primary aldosteronism (PA), sponsored by InnovStone Therapeutics. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
SYH2072
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on NCT07917039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917039.